EyePoint Pharmaceuticals, Inc. (EYPT) Earnings History
Net Loss23 years of earnings data (2003–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
EyePoint Pharmaceuticals, Inc. (EYPT) Earnings Overview
As of June 22, 2026, EyePoint Pharmaceuticals, Inc. (EYPT) reported trailing twelve-month net income of -$272M, reflecting -36.6% year-over-year growth. The company earned $-3.16 per diluted share over the past four quarters, with a net profit margin of -739.4%.
Looking at the long-term picture, EYPT's historical earnings data spans multiple years. The company achieved its highest annual net income of $9M in fiscal 2010.
EyePoint Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including OCUL (-$290M net income, -513.2% margin), RCKT (-$209M net income), ALDX (-$27M net income), EYPT has room to improve margins relative to the peer group. Compare EYPT vs OCUL →
EYPT Earnings vs Peers
Earnings metrics vs comparable public companies
EYPT Historical Earnings Data (2003–2025)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$232M | -77.2% | -$243M | $-3.17 | -739.4% | -776.0% |
| 2024 | -$131M | -84.9% | -$146M | $-2.32 | -302.4% | -337.1% |
| 2023 | -$71M | +30.8% | -$75M | $-1.82 | -153.8% | -163.1% |
| 2022 | -$102M | -75.0% | -$100M | $-2.74 | -247.0% | -240.6% |
| 2021 | -$58M | -28.7% | -$55M | $-2.03 | -158.1% | -149.6% |
| 2020 | -$45M | +20.1% | -$37M | $-3.54 | -131.8% | -108.3% |
| 2019 | -$57M | -6.8% | -$48M | $-6.04 | -278.9% | -235.0% |
| 2018 | -$53M | -187.6% | -$26M | $-11.50 | -1795.7% | -887.3% |
| 2017 | -$18M | +14.2% | -$19M | $-5.23 | -245.2% | -246.4% |
| 2016 | -$22M | -439.5% | -$22M | $-6.81 | -1330.1% | -1344.1% |
| 2015 | $6M | +147.5% | $6M | $2.08 | 23.9% | 24.2% |
| 2014 | -$13M | -12.2% | -$13M | $-4.87 | -384.5% | -388.4% |
| 2013 | -$12M | +52.1% | -$12M | $-5.16 | -555.3% | -561.4% |
| 2012 | -$25M | -187.8% | -$25M | $-11.95 | -704.3% | -715.0% |
| 2011 | -$9M | -198.6% | -$10M | $-4.43 | -173.8% | -201.5% |
| 2010 | $9M | +448.6% | $9M | $4.63 | 38.0% | 39.4% |
| 2009 | -$3M | +96.7% | -$5M | $-1.37 | -20.6% | -38.1% |
| 2008 | -$76M | +27.0% | -$25M | $-41.65 | -2176.9% | -716.4% |
| 2007 | -$104M | -395.7% | -$36M | $-93.93 | -4638.7% | -1590.2% |
| 2006 | -$21M | -87.0% | -$28M | $-27.81 | -1427.1% | -1888.6% |
| 2005 | -$11M | -336.9% | -$10M | $-5.73 | -1776.5% | -1628.8% |
| 2004 | -$3M | -37.8% | -$6M | $-2.08 | -965.0% | -2351.4% |
| 2003 | -$2M | - | -$4M | $-1.35 | -2498.5% | -4838.6% |
Download Data
Export EYPT earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
23+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EYPT — Frequently Asked Questions
Quick answers to the most common questions about buying EYPT stock.
What is EYPT earnings per share (EPS)?
EYPT trailing twelve-month (TTM) diluted EPS is $-3.16, reflecting -36.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2003 to 2025 is available in the table on this page.
What is EyePoint Pharmaceuticals, Inc.'s net income?
EyePoint Pharmaceuticals, Inc. (EYPT) trailing twelve-month net income is $-272M as of 2025. Earnings declined -36.6% year-over-year.
Is EYPT profitable?
EYPT is not currently profitable on a TTM basis, reporting a net loss of $-272M. Net margin is -739.4%. Investors should monitor for a return to profitability.
What is EYPT's earnings growth rate?
EYPT compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2003 to 2025.
What are EYPT's profit margins?
EyePoint Pharmaceuticals, Inc. net profit margin is -739.4%, operating margin is -776.0%, and gross margin is +93.4%. Below-average margins reflect competitive or cost pressures. Return on Equity is -72.2%.
Is EYPT growing earnings?
EYPT earnings are declining — EPS fell -36.6% year-over-year. TTM net income dropped to $-272M. This contrasts with the 5-year CAGR of N/A.
What was EYPT's best earnings year?
EyePoint Pharmaceuticals, Inc.'s highest annual net income on record is $9M, achieved in fiscal year 2010. Earnings history on this page spans 2003 to 2025 and includes all annual and quarterly figures.
What were EYPT's earnings last quarter?
EYPT's most recent reported quarter was Q1 2026. Net income was $-85M with diluted EPS of $-0.99. For a full breakdown of all quarters, see the quarterly earnings table on this page.